Voyager Therapeutics (NASDAQ:VYGR) CEO Alfred Sandrock Sells 11,511 Shares of Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) CEO Alfred Sandrock sold 11,511 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $3.87, for a total value of $44,547.57. Following the completion of the transaction, the chief executive officer owned 472,549 shares in the company, valued at $1,828,764.63. This trade represents a 2.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Alfred Sandrock also recently made the following trade(s):

• On Tuesday, February 24th, Alfred Sandrock sold 14,197 shares of Voyager Therapeutics stock. The stock was sold at an average price of $3.79, for a total value of $53,806.63.
• On Tuesday, February 10th, Alfred Sandrock sold 12,192 shares of Voyager Therapeutics stock. The shares were sold at an average price of $3.78, for a total value of $46,085.76.

Voyager Therapeutics Price Performance

Shares of Voyager Therapeutics stock opened at $3.96 on Friday. The firm has a market cap of $236.02 million, a price-to-earnings ratio of -1.95 and a beta of 1.38. The stock has a 50-day simple moving average of $3.92 and a 200-day simple moving average of $4.18. Voyager Therapeutics, Inc. has a 52-week low of $2.64 and a 52-week high of $5.55.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Monday, March 9th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.08. The firm had revenue of $13.46 million for the quarter, compared to the consensus estimate of $10.49 million. Voyager Therapeutics had a negative return on equity of 51.35% and a negative net margin of 296.53%. As a group, equities research analysts predict that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Institutional Investors Weigh In On Voyager Therapeutics

A number of large investors have recently added to or reduced their stakes in VYGR. Caitong International Asset Management Co. Ltd grew its holdings in Voyager Therapeutics by 42,410.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 15,729 shares of the company’s stock valued at $62,000 after purchasing an additional 15,692 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Voyager Therapeutics by 28.2% in the fourth quarter. Invesco Ltd. now owns 116,000 shares of the company’s stock worth $456,000 after buying an additional 25,522 shares during the last quarter. Sphera Funds Management LTD. lifted its stake in shares of Voyager Therapeutics by 70.1% in the fourth quarter. Sphera Funds Management LTD. now owns 339,761 shares of the company’s stock worth $1,335,000 after buying an additional 140,000 shares during the last quarter. Quadrature Capital Ltd bought a new stake in shares of Voyager Therapeutics during the 4th quarter worth $120,000. Finally, Opaleye Management Inc. acquired a new position in Voyager Therapeutics in the 4th quarter valued at $4,704,000. Institutional investors own 48.03% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on VYGR. Wall Street Zen upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Truist Financial upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, March 17th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Voyager Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.